German drugmaker Merck KGaA lifted its 2026 sales projection for the third time this year, after reporting top-line growth across all three of its businesses.
Blackstone’s Life Sciences unit agreed to pay Pfizer up to $1.5 billion to help develop a GLP-1 receptor. The agreement supports Pfizer’s effort to enter the fast-growing weight-loss drug category.

Comments (0)
No comments yet. Be the first!